In Vitro: ISO-1 (0.1-20 μM; 16 hours) has a slight inhibitory effect on Cox-2 secretion without the addition of recombinant MIF.
In Vivo: ISO-1 (injected intraperitoneally; 3.5-35 mg/kg; twice daily; 2 weeks) improves the survival rate from lethal endotoxemia and shows the anti-inflammatory effect.ISO-1 (intraperitoneal injection; 35 mg/kg; twice daily; 3 days) causes a significant reduction in average implant size and decreases Flk1 expression in implants.